Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (41-50 of 410) with videos related to

Pageof 41
Sort By:
Biofactors (Oxford, England)|June 8, 2012
Ligand binding by PDZ domainsCelestine N Chi, Anders Bach, Kristian Strømgaard, et al.
Nature Reviews. Urology|December 17, 2014
Targeting heat shock proteins in metastatic castration-resistant prostate cancerArun A Azad, Amina Zoubeidi, Martin E Gleave, et al.
Journal of Chemical Theory and Computation|July 21, 2017
eNORA2 Exact NOE Analysis ProgramDean Strotz, Julien Orts, Celestine N Chi, et al.
The Journal of Biological Chemistry|October 5, 2006
Two conserved residues govern the salt and pH dependencies of the binding reaction of a PDZ domainCelestine N Chi, Ake Engström, Stefano Gianni, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 12, 2014
Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancerRobert R Zielinski, Arun A Azad, Kim N Chi, et al.
Neuro-Oncology Practice|July 17, 2023
Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT)Son Tran, Ashley S Plant-Fox, Susan N Chi, et al.
BJU International|October 4, 2018
DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentEvan W Warner, Steven M Yip, Kim N Chi, et al.
RSC Medicinal Chemistry|January 22, 2021
Protein-fragment complex structures derived by NMR molecular replacementFelix Torres, Dhiman Ghosh, Dean Strotz, et al.
Pediatric Dermatology|December 15, 2018
Improvement of hereditary palmoplantar keratoderma with oral trametinibHannah Song, Fiatsogbe Dzuali, Susan N Chi, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysisE S Tsang, C Forbes, K N Chi, et al.
Pageof 41

Showing results (41-50 of 410) with videos related to

Sort By:
Pageof 41
Biofactors (Oxford, England)|June 8, 2012
Ligand binding by PDZ domainsCelestine N Chi, Anders Bach, Kristian Strømgaard, et al.
Nature Reviews. Urology|December 17, 2014
Targeting heat shock proteins in metastatic castration-resistant prostate cancerArun A Azad, Amina Zoubeidi, Martin E Gleave, et al.
Journal of Chemical Theory and Computation|July 21, 2017
eNORA2 Exact NOE Analysis ProgramDean Strotz, Julien Orts, Celestine N Chi, et al.
The Journal of Biological Chemistry|October 5, 2006
Two conserved residues govern the salt and pH dependencies of the binding reaction of a PDZ domainCelestine N Chi, Ake Engström, Stefano Gianni, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|September 12, 2014
Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancerRobert R Zielinski, Arun A Azad, Kim N Chi, et al.
Neuro-Oncology Practice|July 17, 2023
Current advances in immunotherapy for atypical teratoid rhabdoid tumor (ATRT)Son Tran, Ashley S Plant-Fox, Susan N Chi, et al.
BJU International|October 4, 2018
DNA repair defects in prostate cancer: impact for screening, prognostication and treatmentEvan W Warner, Steven M Yip, Kim N Chi, et al.
RSC Medicinal Chemistry|January 22, 2021
Protein-fragment complex structures derived by NMR molecular replacementFelix Torres, Dhiman Ghosh, Dean Strotz, et al.
Pediatric Dermatology|December 15, 2018
Improvement of hereditary palmoplantar keratoderma with oral trametinibHannah Song, Fiatsogbe Dzuali, Susan N Chi, et al.
Current Oncology (Toronto, Ont.)|May 3, 2019
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysisE S Tsang, C Forbes, K N Chi, et al.
Pageof 41